BBLG
Price
$0.36Alerts
Change
+$0.02 (+5.88%)
Updated
Nov 11 closing price
Capitalization
918.87K
112 days until earnings call
Intraday BUY SELL Signals
RXST
Price
$5.28Alerts
Change
+$0.38 (+7.76%)
Updated
Nov 11 closing price
Capitalization
188.83M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BBLG vs RXST

BBLG vs RXST Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BBLG vs. RXST commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBLG is a StrongBuy and RXST is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BBLG with price predictions
Nov 10, 2026

BBLG's RSI Indicator climbs out of oversold territory

The RSI Oscillator for BBLG moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In 40 of the 47 cases the stock moved higher. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for BBLG just turned positive on November 09, 2026. Looking at past instances where BBLG's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.

Following a +6.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBLG advanced for three days, in 145 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

BBLG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBLG as a result. In 83 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBLG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BBLG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.234) is normal, around the industry mean (3.498). P/E Ratio (-1.191) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. BBLG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBLG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for RXST with price predictions
Nov 10, 2026

RXST in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026

RXST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 45 cases where RXST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RXST's RSI Indicator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on RXST as a result. In 66 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for RXST just turned positive on November 09, 2026. Looking at past instances where RXST's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.

Following a +7.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXST advanced for three days, in 236 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 61 cases where RXST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for RXST entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.717) is normal, around the industry mean (4.142). P/E Ratio (-3.982) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.749) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. RXST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BBLG: Fundamental Ratings
BBLG
OUTLOOK RATING
1..100
55
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
7
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BBLGRXST
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BBLG: $0.34 vs. RXST: $4.90)
Brand notoriety: BBLG and RXST are both not notable
BBLG represents the Biotechnology, while RXST is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: BBLG: 18% vs. RXST: 110%
Market capitalization -- BBLG: $918.87K vs. RXST: $188.83M
BBLG [@Biotechnology] is valued at $918.87K. RXST’s [@Medical/Nursing Services] market capitalization is $188.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Biotechnology] industry is $2.23B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBLG’s FA Score shows that 2 FA rating(s) are green while RXST’s FA Score has 2 green FA rating(s).

  • BBLG’s FA Score: 2 green, 3 red.
  • RXST’s FA Score: 2 green, 3 red.
According to our system of comparison, RXST is a better buy in the long-term than BBLG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBLG’s TA Score shows that 5 TA indicator(s) are bullish while RXST’s TA Score has 5 bullish TA indicator(s).

  • BBLG’s TA Score: 5 bullish, 3 bearish.
  • RXST’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both BBLG and RXST are a good buy in the short-term.

Price Growth

BBLG (@Biotechnology) experienced а -3.48% price change this week, while RXST (@Medical/Nursing Services) price change was +6.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.

Reported Earning Dates

BBLG is expected to report earnings on Mar 03, 2027.

RXST is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical/Nursing Services (-2.89% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BBLG and

Correlation & Price change

A.I.dvisor tells us that BBLG and DYAI have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BBLG and DYAI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBLG
1D Price
Change %
BBLG100%
-0.67%
DYAI - BBLG
27%
Poorly correlated
-3.84%
NTLA - BBLG
26%
Poorly correlated
-7.76%
RXST - BBLG
25%
Poorly correlated
+0.82%
PSNL - BBLG
25%
Poorly correlated
-0.44%
DNA - BBLG
25%
Poorly correlated
-2.91%
More

RXST and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXST has been loosely correlated with GMED. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if RXST jumps, then GMED could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXST
1D Price
Change %
RXST100%
+0.82%
GMED - RXST
39%
Loosely correlated
-1.49%
DCTH - RXST
34%
Loosely correlated
-0.84%
STE - RXST
32%
Poorly correlated
+0.07%
UFPT - RXST
32%
Poorly correlated
-1.51%
ESTA - RXST
31%
Poorly correlated
-1.88%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ENFR37.490.53
+1.43%
Alerian Energy Infrastructure ETF (ENFR)
PXE39.000.33
+0.85%
Invesco Energy Exploration & Production ETF (PXE)
BDGS36.500.02
+0.06%
Bridges Capital Tactical ETF (BDGS)
PMAU26.97-0.04
-0.14%
PGIM S&P 500 Max Buffer ETF - August (PMAU)
DFGP52.84-0.30
-0.57%
Dimensional Global Core Plus Fixed Income ETF (DFGP)